A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases OnlyJohanna C. Bendell, Anthony A. Meluch, Andrew Lipman et al.|The Oncologist|2016Cited by 20
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphomaIan W. Flinn, Jesús G. Berdeja, Dana S. Thompson et al.|British Journal of Haematology|2017Cited by 10
Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research InstituteIan W. Flinn, Jesús G. Berdeja, Steven W. Papish et al.|Blood|2012Cited by 1